Hives clinical trials at UCLA
2 research studies open to eligible people
Barzolvolimab in Participants With Chronic Spontaneous Urticaria
open to eligible people ages 18 years and up
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Los Angeles, California and other locations
Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
open to eligible people ages 18 years and up
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Los Angeles, California and other locations
Our lead scientists for Hives research studies include April W. Armstrong, MD, MPH.
Last updated: